VA
TENX icon

VR Adviser’s Tenax Therapeutics TENX Stock Holding History

VR Adviser’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,675,262
Closed -$26.8M – 36
2026
Q1 		$26.8M Buy
+1,675,262
New +$22.7M 1% 23
2025
Q4 		– Sell
-437,708
Closed -$3.33M – 32
2025
Q3 		$3.33M Buy
437,708
+339,144
+344% +$2.07M 0.19% 32
2025
Q2 		$568K Sell
98,564
-109,769
-53% -$634K 0.04% 31
2025
Q1 		$1.36M Hold
208,333
– – 0.12% 32
2024
Q4 		$1.29M Hold
208,333
– – 0.09% 35
2024
Q3 		$721K Buy
+208,333
New +$755K 0.04% 38

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

VR Adviser's TENX Position: Q2 2026 in Review

VR Adviser sold out of Tenax Therapeutics (TENX) in Q2 2026, closing a stake of 1,675,262 shares — an estimated $26.8M sold.

VR Adviser first reported a position in TENX in Q3 2024 and held it in 6 quarters. The position peaked at $26.8M in Q1 2026. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • VR Adviser reported no remaining Tenax Therapeutics position as of Q2 2026 after selling out during the quarter.
  • VR Adviser sold 1,675,262 Tenax Therapeutics shares in Q2 2026, an estimated $26.8M.
  • VR Adviser first reported a position in Tenax Therapeutics in Q3 2024 and held it in 6 quarters.
  • VR Adviser's Tenax Therapeutics position peaked at $26.8M in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.